GMAB 27.38 ▲ 1.11% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Genmab A/S

    NASDAQ: GMAB · Real-Time Price · USD
    27.38
    0.30 (1.11%)
    At close: Sep 04, 2025, 3:59 PM
    27.32
    -0.22%
    Pre-market: Sep 05, 2025, 09:10 AM EDT
    1.11%
    Bid 27
    Market Cap 17.28B
    Revenue (ttm) 17.84B
    Net Income (ttm) 5.64B
    EPS (ttm) 1.93
    PE Ratio (ttm) 14.19
    Forward PE 1.92
    Analyst Buy
    Ask 27.64
    Volume 1,463,247
    Avg. Volume (20D) 1,550,586
    Open 27.11
    Previous Close 27.08
    Day's Range 26.95 - 27.39
    52-Week Range 17.23 - 27.91
    Beta 0.80

    About GMAB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol GMAB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for GMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Genmab A/S is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 day ago
    +4.6%
    Genmab shares are trading higher after the company... Unlock content with Pro Subscription
    4 weeks ago
    +5.49%
    Genmab shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY25 sales guidance.
    news image

    1 day ago · businesswire.com

    Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational...

    news image

    1 week ago · businesswire.com

    Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesute...

    news image

    4 weeks ago · benzinga.com

    Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

    Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...

    news image

    3 weeks ago · zacks.com

    Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade

    The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

    news image

    4 weeks ago · seekingalpha.com

    Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

    Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-F...

    news image

    1 month ago · zacks.com

    GMAB vs. ACAD: Which Stock Is the Better Value Option?

    Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks off...

    1 month ago · youtube.com

    Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

    Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

    1 month ago · youtube.com

    President Trump demands drugmakers slash prices within 60 days

    CNBC's Joe Kernen reports on the latest news.

    news image

    1 month ago · zacks.com

    Genmab (GMAB) Upgraded to Strong Buy: Here's Why

    Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · zacks.com

    Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

    The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

    Add to Watchlist